GlassScriptPhysician profile
Gerald Hagin
NPI 1285606483
$1,329.15
in general payments reported to CMS, 2019-2025
32 companies · $413 in 2025
The $413 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.81 · 2020: $91.50 · 2021: $31.26 · 2022: $122 · 2023: $203 · 2024: $438 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,052.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $188.55 | 2024-2025 | Imfinzi, Enhertu |
| Merck Sharp & Dohme LLC | $157.16 | 2020-2025 | Keytruda, Welireg, Lynparza |
| Boston Scientific Corporation | $111.48 | 2022-2023 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Sobi, INC | $83.79 | 2023-2025 | |
| Lilly USA, LLC | $82.22 | 2020-2025 | Verzenio |
| Daiichi Sankyo INC. | $50.99 | 2022-2024 | Vanflyta |
| Incyte Corporation | $49.45 | 2022-2024 | Monjuvi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $49.13 | 2024-2025 | Iclusig, Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $41.98 | 2022-2024 | |
| Genzyme Corporation | $40.62 | 2022-2024 | |
| Genmab U.S., INC. | $34.07 | 2025 | Tivdak |
| Gilead Sciences, INC. | $33.63 | 2021-2024 | |
| Seagen INC. | $30.41 | 2023 | Adcetris |
| Novartis Pharmaceuticals Corporation | $27.81 | 2024 | |
| Coherus Oncology, INC. | $27.43 | 2025 | Loqtorzi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $26.67 | 2025 | Ojjaara |
| Exelixis INC. | $24.84 | 2024 | Cabometyx |
| Astellas Pharma US INC | $21.87 | 2024 | Padcev |
| Genentech USA, INC. | $21.81 | 2024 | Ocrevus |
| Blueprint Medicines Corporation | $20.40 | 2020 | |
| Beone Medicines USA, INC. | $19.83 | 2025 | Tevimbra |
| Stemline Therapeutics INC. | $19.78 | 2024 | Orserdu |
| Kite Pharma, INC. | $19.34 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $19.15 | 2023 | Epkinly |
| Shire North American Group INC | $18.75 | 2019 | |
| Grifols USA, LLC | $18.26 | 2024 | Gamunex-C |
| Pfizer INC. | $18.10 | 2025 | |
| Mirati Therapeutics, INC. | $18.10 | 2023 | Krazati |
| Alexion Pharmaceuticals, INC. | $14.71 | 2020 | |
| Pharmacosmos Therapeutics INC. | $13.80 | 2025 | Monoferric |
| Rigel Pharmaceuticals, INC. | $13.06 | 2019 | |
| Verastem, INC. | $11.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Hagin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.